Resectable Pancreatic Adenocarcinoma Clinical Trial
Official title:
Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT04940286 -
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT05754788 -
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
|
||
| Recruiting |
NCT05066802 -
A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04858334 -
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
|
Phase 2 | |
| Completed |
NCT00600002 -
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
|
Phase 1 | |
| Recruiting |
NCT03251365 -
Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06423326 -
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04340141 -
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06168552 -
Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03273374 -
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT04915417 -
Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
|
N/A |